Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
4(57.1%)
Phase 2
3(42.9%)
7Total
Phase 1(4)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT01848067Phase 1Completed

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Role: collaborator

NCT02942095Phase 1Completed

Study of Ixazomib and Erlotinib in Solid Tumors

Role: collaborator

NCT02467946Phase 1Completed

Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient

Role: collaborator

NCT03082677Phase 2Completed

Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

Role: collaborator

NCT02441309Phase 2Terminated

A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)

Role: collaborator

NCT02026505Completed

Evaluation of Cardiotoxic Effects of Bortezomib

Role: collaborator

NCT02302846Phase 2Terminated

Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission

Role: collaborator

NCT02280993Phase 1Unknown

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Role: collaborator

All 8 trials loaded